Summary 

Dr Raj Chovatiya addresses the question of how to identify a patient who would benefit from ruxolitinib cream. He explains that the right patients for this treatment are those with mild to moderate symptoms and a body surface area of involvement between 3% and 20%. These criteria are based on the FDA indication and clinical trial design.

In real-world scenarios, patients seeking ruxolitinib cream often have already tried topical corticosteroids or topical calcineurin inhibitors, and a key factor to consider is if patients have not experienced adequate control of their symptoms with these other therapies. The ideal candidate for ruxolitinib cream is someone who desires not only lesional control but also itch control. 

Overall, identifying patients who would benefit from ruxolitinib cream involves assessing the severity of their condition, the affected body surface area, and the inadequacy of previous treatments in controlling their symptoms. 

Key Points 

• The key question is: "Who is the right patient for ruxolitinib cream?" 
• The ideal patient profile includes those with mild to moderate symptoms
• Patients typically have a body surface area of involvement between 3% and 20% 
• Patient candidates have often already tried topical corticosteroids or topical calcineurin inhibitors 
• The target patient is someone who hasn't achieved sufficient control with other therapies
• The desired outcome is not only lesional control, but also itch relief